Compare MHH & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MHH | ACRV |
|---|---|---|
| Founded | 1986 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.3M | 74.0M |
| IPO Year | 2008 | 2022 |
| Metric | MHH | ACRV |
|---|---|---|
| Price | $6.79 | $1.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | ★ $12.75 | $11.50 |
| AVG Volume (30 Days) | 6.1K | ★ 209.9K |
| Earning Date | 10-30-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.13 |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $191,371,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.86 | N/A |
| P/E Ratio | $634.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.50 | $1.27 |
| 52 Week High | $8.37 | $3.56 |
| Indicator | MHH | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 36.21 | 40.93 |
| Support Level | $6.24 | $1.63 |
| Resistance Level | $6.80 | $2.21 |
| Average True Range (ATR) | 0.33 | 0.10 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 20.20 | 27.69 |
Mastech Digital Inc is a provider of Digital Transformation IT Services. The Company offers data & analytics solutions & IT staffing services for both digital & mainstream technologies. The Group has two segments. Its Data & Analytics Services segment delivers specialized data management, data engineering, customer experience consulting, data analytics & cloud services to customers globally. The IT Staffing Services segment combines technical expertise with business process experience to deliver a broad range of services in digital & mainstream technologies. The company derives a majority of its revenue from IT staffing services. Geographically, the majority of revenue is generated from the United States.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.